Clinical Trial Update: SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)

View source ↗

Summary

Integrated efficacy and safety analysis of dalcetrapib (SB-480848) in major adverse cardiovascular events from two large trials in coronary heart disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Dalcetrapib (dalcetrapib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Coronary Heart Disease | Status: COMPLETED